{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:04:13Z","timestamp":1765040653917,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/bjd.15304","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T13:35:07Z","timestamp":1484228107000},"page":"1456-1464","source":"Crossref","is-referenced-by-count":9,"title":["A seamless phase I\/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp"],"prefix":"10.1093","volume":"176","author":[{"given":"J.","family":"Weiss","sequence":"first","affiliation":[{"name":"Gwinnett Clinical Research Center, Inc.; Snellville GA U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Collegium Medicum Berlin; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bukhalo","sequence":"additional","affiliation":[{"name":"Altman Dermatology Associates; Arlington Heights IL U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"\u00d8sterdal","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S; Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bang","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S; Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.W.","family":"Hanke","sequence":"additional","affiliation":[{"name":"Laser & Skin Surgery Center Indiana; Carmel IN U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"10.1111\/bjd.15304-BIB0001|bjd15304-cit-0001","first-page":"294","article-title":"What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: commonly used field-directed and lesion-directed therapies","volume":"89","author":"Berman","year":"2012","journal-title":"Cutis"},{"key":"10.1111\/bjd.15304-BIB0002|bjd15304-cit-0002","first-page":"1727","article-title":"A genetic explanation of Slaughter's concept of field cancerization evidence and clinical implications","volume":"63","author":"Braakhuis","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/bjd.15304-BIB0003|bjd15304-cit-0003","first-page":"w14026","article-title":"Swiss clinical practice guidelines on field cancerization of the skin","volume":"144","author":"Hofbauer","year":"2014","journal-title":"Swiss Med Wkly"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15304-BIB0004|bjd15304-cit-0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.12833","article-title":"A new vision of actinic keratosis beyond visible clinical lesions","volume":"29","author":"Malvehy","year":"2015","journal-title":"Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15304-BIB0005|bjd15304-cit-0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin","volume":"29","author":"Fernandez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15304-BIB0006|bjd15304-cit-0006","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2012.09.051","article-title":"Current issues in the management of actinic keratosis","volume":"68","author":"Ceilley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15304-BIB0007|bjd15304-cit-0007","unstructured":"Picato\u00ae Prescribing information https:\/\/www.picato.com\/_pdf\/PrescribingInformation.pdf"},{"key":"10.1111\/bjd.15304-BIB0008|bjd15304-cit-0008","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.15304-BIB0009|bjd15304-cit-0009","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","article-title":"Long-term follow-up trial of ingenol mebutate gel for the treatment of actinic keratoses","volume":"149","author":"Lebwohl","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.15304-BIB0010|bjd15304-cit-0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjd.14245","article-title":"A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of ingenol disoxate in patients with actinic keratosis","volume":"174","author":"Sinnya","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15304-BIB0011|bjd15304-cit-0011","first-page":"166","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies","volume":"13","author":"Swanson","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15304-BIB0012|bjd15304-cit-0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13555-014-0059-9","article-title":"A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosistherapy with ingenol mebutate","volume":"4","author":"Rosen","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1111\/bjd.15304-BIB0013|bjd15304-cit-0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel trial of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1111\/bjd.15304-BIB0014|bjd15304-cit-0014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15304-BIB0015|bjd15304-cit-0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15304-BIB0016|bjd15304-cit-0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"key":"10.1111\/bjd.15304-BIB0017|bjd15304-cit-0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15304-BIB0018|bjd15304-cit-0018","first-page":"144","article-title":"Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15304-BIB0019|bjd15304-cit-0019","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15304-BIB0020|bjd15304-cit-0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","article-title":"Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis","volume":"24","author":"Loven","year":"2002","journal-title":"Clin Ther"},{"key":"10.1111\/bjd.15304-BIB0021|bjd15304-cit-0021","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/lsm.20379","article-title":"A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses","volume":"38","author":"Ostertag","year":"2006","journal-title":"Lasers Surg Med"},{"key":"10.1111\/bjd.15304-BIB0022|bjd15304-cit-0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/dth.12334","article-title":"Daylight methyl-aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment of actinic keratoses: an intraindividual comparative analysis","volume":"29","author":"Genovese","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1111\/bjd.15304-BIB0023|bjd15304-cit-0023","first-page":"1353","article-title":"Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT","volume":"13","author":"Berman","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15304-BIB0024|bjd15304-cit-0024","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000447355","article-title":"A randomized split-face clinical trial of photodynamic therapy with methyl aminolevulinate versus ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and scalp","volume":"232","author":"Zane","year":"2016","journal-title":"Dermatology"},{"key":"10.1111\/bjd.15304-BIB0025|bjd15304-cit-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TCRM.S1769","article-title":"Review of photodynamic therapy in actinic keratosis and basal cell carcinoma","volume":"4","author":"Ericson","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/bjd.15304-BIB0026|bjd15304-cit-0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jval.2015.11.014","article-title":"Evaluation of resource utilization and treatment patterns in patients with actinic keratosis in the United States","volume":"19","author":"Asche","year":"2016","journal-title":"Value Health"},{"key":"10.1111\/bjd.15304-BIB0027|bjd15304-cit-0027","first-page":"35","article-title":"Non-adherence to topical treatments for actinic keratosis","volume":"8","author":"Shergill","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1111\/bjd.15304-BIB0028|bjd15304-cit-0028","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ijd.12840","article-title":"A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis","volume":"54","author":"Stockfleth","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.15304-BIB0029|bjd15304-cit-0029","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2015.01.036","article-title":"Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes","volume":"72","author":"Augustin","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15304\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:25:16Z","timestamp":1676384716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/176\/6\/1456\/6687226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15304","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"type":"print","value":"0007-0963"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}